Factor (F)XIII is a tranglutaminase enzyme that catalyses the formation of -(-glutamyl)lysyl isopeptide bonds into protein substrates. The plasma form, FXIIIA 2 B 2 has an established function in hemostasis, where its primary substrate is fibrin. A deficiency in FXIII manifests as a severe bleeding diathesis underscoring its importance in this pathway. The cellular form of the enzyme, a homodimer of the A subunits, denoted FXIII-A, has not been studied in as extensive detail. FXIII-A was generally perceived to remain intracellular, due to the lack of a classical signal peptide for its release. In the last decade emerging evidence has revealed that this diverse transglutaminase can be externalised from cells, by an as yet unknown mechanism, and can cross-link extracellular substrates and participate in a number of diverse pathways. The FXIII-A gene (F13A1) is expressed in
Introduction
In 1948 Laki and Lorand characterised a labile component of blood that when combined with Ca 2+ rendered a clot insoluble [1] . The protein was later isolated and named fibrin stabilising protein [2] .
Duckert et al [3] then reported that deficiency of fibrin stabilizing factor manifests as a severe bleeding diathesis. Subsequently in 1963, the International Committee on Blood Clotting Factors acknowledged this protein as a clotting factor and termed it factor XIII (FXIII). Our knowledge of FXIII has progressed significantly since these early informative observations. It is now clear that in addition to the essential role of FXIII in hemostasis it functions in a variety of other systems ranging from wound healing and angiogenesis [4] to stabilisation of the bone matrix [5] . Once activated FXIII (FXIIIa) elicits transamidase activity that introduces -(-glutamyl)lysyl isopeptide cross-links into protein substrates. It can incorporate cross-links into single protein substrates, such as fibrin, or can cross-link different proteins to each other, which can impact on their biological function [6] .
In plasma, FXIII exists as a zymogen heterotetramer (FXIII-A 2 B 2 ) [7] with two catalytic A subunits and two inhibitory carrier B subunits. [8] . FXIII-B is synthesised and secreted by hepatocytes [9, 10] , however the source of plasma FXIII-A subunit has been debated for some years. The gene, F13A1, is largely expressed in cell of bone marrow origin, but it lacks an identifiable endoplasmic reticulum (ER) signal sequence and is excluded from the classical ER-Golgi pathway in nucleated cells [11] .
Platelets were projected to be the source of the FXIII-A subunit in plasma [12, 13] , but this was ruled out, as levels were unchanged in thrombocytopenic mice [14] . Recent observations, in tissue specific mouse knockouts of FXIII-A, now pinpoint resident tissue macrophages as the cellular source of plasma FXIII-A [15] . Plasma FXIII-A 2 B 2 requires the concerted action of thrombin and calcium to be activated [16, 17] . The activation peptides which flank each of the FXIII-A subunits are initially cleaved by thrombin, which destabilizes the interaction between the FXIII-A and FXIII-B subunits [18] . The subsequent binding of calcium ions to defined sites on the FXIII-A subunits instigates dissociation of the FXIII-B subunits and activation peptides [19] .
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This article is protected by copyright. All rights reserved. The mechanism of FXIII-A release from these cells remains an enigma, due to the lack of signal sequence as stated, and it is also absent from the ER-Golgi secretory pathway in nucleated cells [11] .
However, FXIII-A in monocyte-macrophages is reportedly directed to the plasma membrane in association with Golgi vesicles [14] indicating that it is secreted via an alternative pathway. This review will focus on the multifarious actions of cellular FXIII-A and discuss whether it is capable of mediating extracellular cross-linking as well as intracellular functions despite its clear lack of a signal peptide for secretion.
FXIII-A in Platelets
Platelets harbour remarkably high concentrations of FXIII-A within their cytoplasm [35, 36] , with a single platelet accruing 60 ± 10 fg, corresponding to 3% of total platelet protein [37] . -granules reportedly contain a minor pool of FXIII in the A 2 B 2 form which is endocytosed from plasma alongside fibrinogen [35, 38] , however the concentrations are so low it is often not detectable in the platelet secretome [39, 40] . Early studies on platelet FXIII-A concluded that it was not involved in haemostasis, as it did not form part of the platelet secretome [39], but our recent observations indicate that FXIII-A is translocated from the cytoplasm to the surface of activated platelets where is actively retained [40] .
Platelet FXIII-A in hemostasis
The role of plasma FXIIIA 2 B 2 in haemostasis is well-established; it confers mechanical stability to thrombi by cross-linking the -and -chains of fibrin, and provides protection against fibrinolytic breakdown by cross-linking inhibitors of fibrinolysis to fibrin [41] [42] [43] . Our laboratory has shown that flow is required to visualize the impact of FXIIIA 2 B 2 on fibrinolysis [44] and that the antifibrinolytic action of this transglutaminase is mediated exclusively by cross-linking  2 -antiplasmin ( 2 AP) to fibrin [45] . Rijken and colleagues subsequently reported that compaction or retraction of fibrin clots reveals the strong antifibrinolytic effect of FXIIIA 2 B 2 [46] . The authors also confirm our observations that cross-linking of 2AP is required for the antifibrinolytic effect of FXIII to be visualised rather than by fibrin-fibrin cross-links [46] . Plasma FXIIIA 2 B 2 , but not platelet FXIII-A, also aids in the retention of red blood cells in clots through fibrin -chain cross-linking which has a direct impact on the overall size of clots [47] [48] [49] .
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Platelet FXIII-A was previously shown to stabilize clots, by inducing the formation of high molecular weight -dimer and -polymer [50] [51] [52] [53] [54] and cross-linking  2 AP to fibrin [50, 53] . The conundrum is that FXIII-A was not found within the secretome of platelets. Our laboratory has now shown that strong agonist stimulation of platelets induces translocation of FXIII-A from the cytoplasm to the platelet membrane where it is actively retained and can participate in extracellular cross-linking reactions [40] . The intensity of FXIII-A staining on the surface of activated platelets increases as a function of time, particularly in those platelets directly associated with collagen fibres ( Figure 1A ).
Our work clearly highlights a role for FXIII-A, externalised during platelet activation, in stabilizing thrombi via cross-linking of  2 AP to fibrin [40] . The relative contribution of plasma FXIIIA 2 B 2 versus platelet-derived FXIII-A to thrombus stability requires clarification, but it is unlikely to be uniform throughout the thrombus, with the balance tipping toward FXIII-A in platelet-rich areas of the hemostatic plug, where solute transport of plasma FXIIIA 2 B 2 is low.
Distribution of FXIII-A on the activated platelet surface is dependent on the subpopulation of platelets ( Figure 1B) , with PS-negative or spread platelets exhibiting diffuse staining across the membrane with a high concentration over the granulomere [40] . In PS-positive procoagulant platelets, FXIII-A was present only in the protruding 'cap' [40] . These 'caps' bind a number of other hemostatic proteins including fibrinogen [55] , plasminogen and PAI-1 [56] . The 'caps' of platelets have recently been described as the 'platelet body' which the authors speculate is the remnant of organelles following ballooning of the platelet following strong agonist stimulation [57] . Ballooning transpires due to expansion of the platelet membrane, as a result of rapid influx of water and Na + and Cl -ions. These platelets bind both procoagulant factor Xa and factor Va to the ballooned area and the platelet body thereby augmenting thrombin generation [58] . The collection of both procoagulant and pro-and anti-fibrinolytic proteins in these PS-positive platelets suggests they participate not only thrombus formation, but also the stability and breakdown of the thrombus.
FXIII-A also functions in the formation of PS-positive platelets [59] , by acting in concert with calpain to reduce the adhesive function of IIbβ3, in a process that appears to be a prerequisite for their formation.
The method of externalization of platelet FXIII-A remains to be elucidated, but clearly occurs in response to external stimuli [40] . Reduced levels of FXIII-A were detected on stimulation of platelets with TRAP-6, compared to thrombin, and when platelets were treated with the Gly-Pro-Arg-Pro peptide, which inhibits fibrin polymerisation. The connection between platelet-associated fibrin and FXIII-A exposure suggests that IIbβ3 may serve as a 'bridge' for FXIII-A to traverse to access the fibrin network [40] . Fibrin associated directly with the platelet surface is exceptionally resilient to fibrinolysis [56, [60] [61] [62] [63] , suggesting that platelet-derived FXIII-A and other anti-fibrinolytic proteins contribute to this heightened resistance at least in the early stages of thrombus formation.
Platelet FXIII-A in clot retraction
Clot retraction is the process by which fully-formed clots are compacted to limit vessel blockage and prevent leakage from the wound site. Platelets operate contractile machinery to reel in the surrounding fibrin network, expedited by bi-directional IIbβ3 signalling [64] . The integrin IIbβ3
acts as a molecular bridge between extracellular fibrinogen and the intracellular actin cytoskeleton via sphingomyelin-rich lipid rafts [65] . The cytoskeleton interacts with the 3 subunit tails via the adapter proteins talin and vinculin [66] . During clot retraction, fibrin bound to IIbβ3 triggers outside-in signalling [67] , resulting in the contraction of the actin cytoskeleton. FXIIIA 2 B 2 contributes to the strength and rigidity of the condensed clot by cross-linking fibrin, and by enhancing platelet spreading [68] . Conflicting evidence exists on the effects of platelet FXIII-A on clot retraction. Early reports found that clot retraction was normal in FXIII-deficient patients [69] [70] [71] . More recently, Kasahara et al., [65, 72] , have demonstrated that clot retraction was significantly impaired in the absence of platelet FXIII-A transglutaminase activity in PRP from FXIII-A knockout mice [65, 72] . In contrast, Kattula et al., [49] found that platelet FXIII-A did not contribute to the weight of clots formed from reconstituted FXIII-depleted plasma reconstituted with red blood cells compared with those containing FXIII-deficient platelets. Methodological differences in the two studies may account for these reported discrepancies, however, it is evident that further studies are required to confirm the role of platelet FXIII-A functions in clot retraction in vivo.
Other roles of platelet FXIII-A
The adhesive ability of IIbβ3 is thought to be negatively regulated by FXIII-A and calpain, which limits platelet aggregate formation and thrombus growth [59] . These observations were made primarily in collagen-adherent platelets with prolonged elevations in cytosolic calcium, leading to a specific reduction in IIbβ3 adhesive function. During thrombus formation, a number of phenotypically different platelet populations arise [59, [73] [74] [75] . These populations play different roles in the regulation of the thrombus microenvironment. Adherent platelets, with activated IIbβ3, bind other platelets and fibrin and ensure thrombus stability [76] , while procoagulant platelets lack functional IIbβ3. Platelet FXIII-A also drives formation of a specific subtype of procoagulant platelets that retain an alpha-granule protein 'coat' on their surface [77] [78] [79] . Transglutaminase activity cross-links -granule proteins to serotonin where they can then be retained on the platelet surface by binding to low affinity serotonin binding sites on fibrinogen or thrombospondin [77, 79] .
It has been proposed that platelet FXIII-A is not a requirement for generation of coated platelets, due to their formation in FXIII deficient mice [80] . However, this could be due to a compensatory upregulation of other transglutaminases in FXIII-A deficient platelets [80] . In line with this FXIII-A deficient platelets have also been found to accelerate cross-linking [53] .
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Under low shear conditions fibrin formation on platelets forms a 'star-like' pattern on the platelet surface [81] . FXIII-A and IIbβ3 play synergistic roles in aiding formation of these fibrin protrusions.
In the absence of FXIII-A and IIbβ3, fibrin formation still occurs on the platelet surface, however fibres are orientated in the direction of flow [78] , suggesting that early cross-links facilitate fibrin polymerisation against the direction of flow.
It has been suggested that FXIII-A functions in formation of protrusions such as filopodia and lammelipodia which aid in platelet adhesion, spreading and clot retraction [82] . A number of proteins involved in cytoskeletal remodelling are cross-linked by FXIII-A, including; actin [83, 84] , GPIIb, GPIII, myosin, tropomyosin [84] , talin, vinculin, filamin [82] , and Thymosin beta4 [85] . FXIII-A associates with the cytoskeleton upon platelet activation, however, this is dependent on actin polymerisation, as the phallotoxin cytochalasin D inhibited this translocation [82] . Interestingly, cross-linking of vinculin was dependent on aggregation. Vinculin cannot be cross-linked to itself, but is cross-linked to a number of other cytoskeletal proteins [82] , suggesting FXIII-A may localise key cytoskeletal proteins during remodelling. FXIII-A directly associates with HSP27 in activated platelets [86] . HSP27 functions as a molecular chaperone and rapidly interacts with the actin cytoskeleton upon platelet stimulation. It is plausible that HSP27 acts as a chaperone for translocation of FXIII-A from the platelet cytoplasm to the outer membrane via the actin cytoskeleton.
FXIII-A in leukocytes
FXIII-A is located in the cytoplasm of macrophages and monocytes [87] , Leukocyte FXIII-A has been implicated in a number of intra-and extracellular processes, but as yet there is no defined route of externalisation FXIII-A is expressed on the cell surface of monocytes and macrophages [88] 
Accepted Article
Phagocytosis is the active ingestion and breakdown of microbes or other foreign particles by cells such as monocytes and macrophages. Phagocytic processes are driven by a finely controlled rearrangement of the actin cytoskeleton [95] . Considering the key role of FXIII-A in regulating cytoskeletal proteins it is perhaps not surprising that it is directly linked to this process [82] [83] [84] .
Studies have indicated that FXIII-A activity may play a role in increasing the amount of phagocytosis in monocytes and macrophages [96] .
Phagocytosis is positively correlated with FXIII-A expression in myelomonocytic cells [97] . In accordance with this Fc and complement receptor mediated phagocytosis is impaired in monocytes and macrophages following inhibition of FXIII-A and in FXIII-A-deficient mice [96] . FXIII-A is known to be upregulated during the maturation of monocyte-derived dendritic cells and actively assists migration of these cells [98] . Together these data implicate FXIII-A in the phagocytic and/or migration capacity of these cells, however there may be a degree of redundancy in the system, as phagocytosis is only slightly impaired in the absence of FXIII-A [96] .
The role of cellular FXIII-A in lymphocytes in haemostasis has not been widely explored, however macrophages and monocytes are able to cross-link fibrin-and -chains [88, 99] , suggesting a potential role in thrombus stabilisation. Interestingly, thrombin treatment of monocytes does not augment exposure of FXIII-A [88] , suggesting these cells may contribute to haemostasis in a situation where there is also an increase in the type 2 immune response, for example in a wound healing capacity.
FXIII-A in bone
Bone is a dynamic mineralized tissue which undergoes continuous remodelling in the form of bone resorption by osteoclasts and formation by osteoblasts. The processes of bone formation and resorption are influenced by many chemical and mechanical factors and an imbalance can severely impact on bone quality [100] . FXIII-A is present in a number of cell types in mineralized tissues including chondrocytes [31-33], osteocytes [101] and osteoblasts [5, 101] where it is both expressed on the cell surface and secreted into the extracellular matrix. FXIII-A contributes to the formation and stabilisation of connective tissue in bone by cross-linking a number of different substrates.
Secreted osteoblast FXIII-A aids in the incorporation of fibronectin into the bone matrix [102, 103] thereby promoting formation of an insoluble matrix. This matrix forms a scaffold for other proteins to adhere to, including type 1 collagen [104] . Surface-associated osteoblast FXIII-A is involved in stabilizing the interaction between microtubules and the plasma membrane, which in turn enhances the secretion of collagen [102, [105] [106] [107] . Collagen is the principal component of bone matrix and it appears that both FXIII-A activity and fibronectin are essential for normal collagen deposition [102, 103] . Extracellular collagen is a prerequisite for secretion of FXIII-A from osteoblasts and in line with this observation, increased levels of collagen enhance expression of FXIII-A mRNA [106] . Osteoblast
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This article is protected by copyright. All rights reserved. . FXIII-A has also been detected as a 37 kDa fragment in chondrocytes [110] , cultured MC3T3-E1 osteoblast cells [101, 102] primary mouse osteoblast cells, mouse macrophage and chondrocyte extracts and in rat bone [101] . The 37 kDa fragment, postulated to arise from proteolytic cleavage of the full-length form, has a different subcellular localisation to full length FXIII-A in osteoblasts [101] . However, Cordell and colleagues [111] suggest that the mAb-AC-1A1 antibody used in these studies cross-reacts with transaldolase-1 (37 kDA) and other off-target antigens in cultured cells. Furthermore, this 37 kDa band is present in a number of cell types that lack FXIII-A protein and mRNA [111] and in bone and heart tissue from FXIII-A deficient mice [111] . FXIII-A and TG2 deficient mice also appear to exhibit normal bone deposition [111] , suggesting that transglutaminase activity is not required for these processes in vivo. It is evident from the tangled literature that further work is necessary to define the forms of FXIII-A in bone and confirm its role in the formation, maintenance and repair of mineralized tissues in vivo.
Cellular FXIII-A in disease
The vast number of functions carried out by cellular FXIII-A has inevitably resulted in its contribution to a number of different disease states, where it has been found to play beneficial and detrimental roles.
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FXIII-A in lung disease
Cellular FXIII-A and plasma FXIIIA 2 B 2 have been implicated in the pathogenesis of lung diseases. In many forms of acute and chronic lung inflammation, fibrin deposition occurs as a result of increased vascular permeability eventually leading to fibrosis [112] . Cellular FXIII-A from injured alveolar macrophages and plasma FXIIIA 2 B 2 from leaky capillaries have been detected in the bronchoalveolar lavage fluid of children with chronic bronchoalveolar inflammatory conditions, along with D-dimer [113] . These data suggest that FXIII is involved in stabilising fibrin deposits in the extravascular compartment of the lung tissues in these diseases. Increased FXIII-A release from dendritic cells is also detectable in bronchiolar lavage fluid following allergen challenge in asthmatic patients. This suggests a potential role for FXIII-A in airway obstruction in this disease [114] , perhaps through the reinforcement of fibronectin deposits, which are involved in pathogenic airway remodelling in asthma [115] .
FXIII-A in vascular disease
Long-term alterations in blood flow ultimately give rise to vascular remodelling [116] , a process in which FXIII-A has been implicated [117] . Blood vessel widening occurs in response to increased blood flow, decreased blood flow results in vessel narrowing [118, 119] and vessel walls thicken in response to high blood pressure [120] . Macrophage FXIII-A may participate in flow-induced remodelling of vessels [121] . Zhou et al., [121] demonstrated that expression of the CXCR3 receptor is necessary for inward perivascular remodelling induced by alterations in blood flow. This CXCR3-dependant accumulation of macrophages during perivascular remodelling enhanced expression of FXIII-A mRNA [121] , suggesting that the transglutaminase may function by stabilizing the remodelled vascular wall.
Hypertension is characterized as long term elevation in blood pressure and is a significant risk factor for the development of atherosclerosis. Infiltration of the arterial wall by monocytes, macrophages and T-cells leads to formation of new connective tissue, which together with the infiltrating leukocytes, forms an atherosclerotic lesion [122] . The angiotensin II (ATII) signalling system is involved in multiple regulatory processes, including the control of blood pressure through vasoconstriction. ATII signalling is also implicated in a number of pathological diseases, such as hypertension and atherosclerosis [123] . Monocyte FXIII-A plays a pathogenic role in hypertensive disease due to its ability to increase the signalling capacity of the angiotensin receptor (ATI) [124] .
ATI receptor dimerization occurs in the presence of ATII, and FXIII-A subsequently facilitates covalent cross-linking of the ATI monomers, resulting in increased receptor capacity for signalling and desensitization [124] . Hypertensive patients display an increase in both monocyte FXIII-A and angiotensin-converting-enzyme (ACE)-dependant ATII production and storage [124] . Increased crosslinked AT1 dimers have been found in an ApoE-/-model of atherosclerotic mice and inhibition of ACE and cellular FXIII-A reduced atherosclerotic lesion area and attenuated the recruitment of
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leukocytes into the aorta [124] . Platelet-derived FXIII-A has also been identified in atherosclerotic plaques [125] , suggesting that the function of platelet FXIII-A is not confined to hemostasis and may function in pathogenic situations, such as stabilization of atherosclerotic lesions.
FXIII-A in cardiac disease
Plasma FXIIIA 2 B 2 and platelet FXIII-A have been found to contribute to the integrity of the cardiac vessel wall. A number of cardiac pathologies are observed in FXIII deficient mice, most of which are exacerbated by the combined absence of both cellular and plasma FXIII [126] . In these cases, hemorrhage and fibrosis resulting from lack of plasma FXIIIA 2 B 2 induce initial damage to cardiac tissue, this is followed by delayed wound healing, due to the absence of cellular FXIII-A in leukocytes in these tissues [126] . FXIII-A is present in resident monocytes and macrophages in normal cardiac tissue, and following coronary ligation [127] . FXIII deficient mice exhibit an increased incidence of cardiac rupture, which can be circumvented by infusion of FXIIIA 2 B 2 , although ventricular remodelling in these mice remained diminished [127] . High levels of FXIII transglutaminase activity was observed in healing infarct tissue, suggesting its active participation in the wound healing response. A reduction in leukocytes has been documented in cardiac tissue in FXIII-A deficient mice [128] , which could be attributed to the role of FXIII-A in cell migration, thus exacerbate the impaired wound healing observed.
FXIII-A in inflammatory disease
The expression of FXIII-A in a number of inflammatory cells also implicates it in the pathogenesis of certain inflammatory disorders. In ulcerative colitis, reduced expression of both cellular FXIII-A and plasma FXIIIA 2 B 2 is evident due to upregulation of the M1 immune response. The reduction of FXIII levels in this case will affect its capacity to aid in phagocytosis and cell migration and may contribute to the prolongation and severity of the disease [129] . The contribution of FXIII-A to inflammatory arthritis is also evident in collagen-induced arthritis models FXIII-A deficient mice. There was a significant reduction in osteoclast differentiation in FXIII-A deficient mice which limited disease progression. FXIII-A deficient mice also displayed reduced deposition of fibrin in the extracellular spaces within the knee joints leading to a reduction in the retention of inflammatory macrophages [130] . These results clearly show that eliminating FXIII-A limits inflammatory arthritis and protects from cartilage and bone destruction, thus suggesting that inhibition of this transglutaminase is a potential therapeutic strategy in arthropathies and other degenerative bone diseases.
FXIII-A in diabetes and obesity
Pancreatic islet  cells harbours FXIII-A which exerts transglutaminase activity in response to prolonged spikes in cytosolic Ca 2+ [131] . Glucose-stimulated insulin secretion in -cells is inhibited upon treatment with a transglutaminase inhibitor, suggesting that FXIII-A activity is involved in
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insulin regulation [131] . Interestingly, a recent study has identified a possible connection between FXIII-A and type 2 diabetes in a mouse model of obesity-induced chronic low-grade inflammation, mimicking that found in type 2 diabetes [132] . Mice treated with low dose pro-inflammatory cytokines exhibited reduced glucose-stimulated insulin secretion and increased basal Ca 2+ levels, resulting in reduced expression of the FXIII-A gene (F13A1) [132] . Identification of F13A1 as a novel stress-inhibited gene in islets provides a promising lead to pursue in the dysfunction that occurs in these cells during the development of type 2 diabetes.
Single nucleotide polymorphisms SNPs in F13A1 correlate with increased body mass index and an increased incidence of type 2 diabetes [133] . A recent study performed by Myneni et al., [34] suggests that FXIII-A may contribute to obesity and weight gain. FXIII-A is expressed in adipose tissue where it is enhances proliferation of preadipocytes and stabilises the fibronectin matrix.
[34].
In line with these observations, FXIII-A deficient mice are protected against insulin resistance, they
show signs of metabolically healthy obesity [134] . Further work is urgently required to clarify the direct role of FXIII-A in attenuating type 2 diabetes and obesity.
FXIII-A in cancer
FXIII-A has been identified in a number of leukemic cell types including megakaryoblasts, promyeloblasts, monoblasts and lymphoblasts [135, 136] and FXIII-A expression in leukemic cells is associated with reduced patient survival in acute promyelocytic leukemia [137] . In contrast, a recent study has shown that FXIII-A expression in children with B-cell precursor acute lymphoblastic leukemia was associated with patient survival [138] . Further studies in this area are essential to delineate the role of FXIII-A in leukemic cells in contributing towards disease progression.
Summary and future perspectives
Plasma FXIIIA 2 B 2 was classified as a coagulation factor in the 1960's and is largely found in complex with the precursor of its principal target protein, fibrinogen. The clear bleeding phenotype of individuals deficient in FXIII is testimony to its essential function in hemostasis. However, there has been ambiguity surrounding the true function of the cellular form of FXIII-A. This can in part be ascribed to the fact that while FXIII-A is expressed by numerous cell types, mainly those of hematopoietic origin, it does not contain a classical endoplasmic reticulum signal peptide for secretion in nucleated cells [11] . This has hampered research into FXIII-A, but accumulating evidence now indicates that it is a diverse cellular enzyme that cross-links numerous substrates within the intracellular and extracellular environment (summarised in Figure 2 ). Recent observations accrediting the cellular source of the plasma FXIII-A subunit to resident tissue macrophages [15] has significantly advanced our knowledge, but as yet the mechanism involved in its secretion remain an enigma. Given the nature of this enzyme, and the fact that isopeptide bonds can be formed between glutamine donors and lysine acceptor residues in a wide range of proteins, it
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is perhaps not surprising that FXIII-A functions in such an array of biological processes. Nonetheless, the absence of an inhibitor of FXIII-A suggests that the environment and kinetics of this transamidase enzyme must regulate its function, but direct evidence on this is scant. In conclusion, it is evident that FXIII-A is a broad spectrum enzyme that is largely indiscriminate in its ability to cross-link protein substrates, but there is still much to be uncovered in relation the mechanism of secretion from cells of bone marrow lineage and direction of its function in different biological and pathophysiological processes.
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